93 related articles for article (PubMed ID: 2232966)
41. IL-2 receptors, NK and LAK cytotoxicity of lymphocytes in breast carcinoma during prolonged thymopentin therapy.
Mazzarino C; Nicosia A; Monte V; Petralia S; Garraffo C; Girlando A; Santoro S; Malaponte G
J Nucl Med Allied Sci; 1990; 34(4 Suppl):161-2. PubMed ID: 2128707
[No Abstract] [Full Text] [Related]
42. Effects of a Chinese medical herbs complex on cellular immunity and toxicity-related conditions of breast cancer patients.
Zhuang SR; Chiu HF; Chen SL; Tsai JH; Lee MY; Lee HS; Shen YC; Yan YY; Shane GT; Wang CK
Br J Nutr; 2012 Mar; 107(5):712-8. PubMed ID: 21864416
[TBL] [Abstract][Full Text] [Related]
43. Immunological investigation and immunotherapy approaches in cancer patients.
Luporini G; Clerici M; Montinari F; Fraschini P; Besana C
Boll Ist Sieroter Milan; 1975 Oct; 54(4):331-6. PubMed ID: 1203089
[TBL] [Abstract][Full Text] [Related]
44. [Effect of peroral BCG therapy on immune status of breast cancer patients during chemotherapy].
Melchert F; Kreienberg R; Lemmel EM
Arch Gynecol; 1979 Jul; 228(1-4):610-1. PubMed ID: 485507
[No Abstract] [Full Text] [Related]
45. [Indices of the cellular reactions of the immune process in acute stress and its thymopentin correction].
Vazhnichaia EM; Tarasenko LM; Deviatkina TA
Fiziol Zh (1978); 1992; 38(1):108-11. PubMed ID: 1555717
[TBL] [Abstract][Full Text] [Related]
46. [The immunomodulating action of thymopentin in acute and chronic stress].
Vazhnichaia EM; Tarasenko LM; Deviatkina TA; Klusha VE
Farmakol Toksikol; 1991; 54(1):38-40. PubMed ID: 1860496
[TBL] [Abstract][Full Text] [Related]
47. Ovarian cancer: where to next?
Ozols RF; Young RC
Semin Oncol; 1991 Jun; 18(3):307-10. PubMed ID: 2042067
[No Abstract] [Full Text] [Related]
48. Cell-mediated immunity in patients with tumors of the female genital tract.
Zulli P
Patol Clin Ostet Ginecol; 1977; 5(4):165-74. PubMed ID: 606604
[No Abstract] [Full Text] [Related]
49. [Comparison of tumor-associated cellular and nonspecific humoral immune parameters in immunologic monitoring of breast cancer].
Mallmann P; Koenig UD; Krebs D
Onkologie; 1989 Jun; 12 Suppl 3():9-14. PubMed ID: 2691947
[TBL] [Abstract][Full Text] [Related]
50. Intraperitoneal immunotherapy for ovarian cancer with alpha interferon.
Berek JS
Eur J Cancer; 1992; 28A(4-5):719-21. PubMed ID: 1524888
[No Abstract] [Full Text] [Related]
51. Alterations of cell-mediated immune response following cardiac surgery.
Markewitz A; Faist E; Weinhold C; Lang S; Endres S; Hültner L; Reichart B
Eur J Cardiothorac Surg; 1993; 7(4):193-9. PubMed ID: 8481256
[TBL] [Abstract][Full Text] [Related]
52. [A study on the effectiveness of the adjuvant chemotherapy and immunotherapy and its correlation with cellular immunity].
Sachira ; Onda M; Tokunaga A
Nihon Ika Daigaku Zasshi; 1989 Jun; 56(3):308-12. PubMed ID: 2753993
[No Abstract] [Full Text] [Related]
53. [15 years results in chemotherapy of ovarian cancer and recent findings on adjuvant immunotherapy in gynecology].
Limburg H; Brachetti AK; Riede UN
Arch Gynecol; 1979 Jul; 228(1-4):444. PubMed ID: 485424
[No Abstract] [Full Text] [Related]
54. Impact of thymopentin on the incidence and severity of postoperative infection: a randomized controlled trial.
Braga M; Costantini E; Di Francesco A; Gianotti L; Baccari P; Di Carlo V
Br J Surg; 1994 Feb; 81(2):205-8. PubMed ID: 8156337
[TBL] [Abstract][Full Text] [Related]
55. Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations.
Hsieh KH; Shaio MF; Liao TN
Arch Dis Child; 1992 Sep; 67(9):1095-102. PubMed ID: 1329673
[TBL] [Abstract][Full Text] [Related]
56. Immune effects of relaxation during chemotherapy for ovarian cancer.
Lekander M; Fürst CJ; Rotstein S; Hursti TJ; Fredrikson M
Psychother Psychosom; 1997; 66(4):185-91. PubMed ID: 9259041
[TBL] [Abstract][Full Text] [Related]
57. Active specific immunotherapy of human solid tumors.
Rosato FE
Ann N Y Acad Sci; 1976; 277(00):332-8. PubMed ID: 1069552
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy for breast cancer: is it feasible?
Clarke E
Immunotherapy; 2015; 7(11):1135-43. PubMed ID: 26567869
[No Abstract] [Full Text] [Related]
59. Role of tumor immunity in ovarian cancer.
Humphrey L; Panoussopoulos D; Volenec FJ; Masterson BJ; Jewell W
South Med J; 1977 Oct; 70(10):1186-7. PubMed ID: 910169
[TBL] [Abstract][Full Text] [Related]
60. [Problems and perspectives of immunotherapy in modern ENT-oncology].
Pogosov VS; Dmitriev AA; Antoniv VF; Daikhes NA; Sarkisova FR
Vestn Otorinolaringol; 1991; (4):67-70. PubMed ID: 1957453
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
